Sermorelin is an analog of growth hormone-releasing hormone (GHRH) and was recently developed to help maintain some of the positive effects of natural GHRH while avoiding unwanted effects.
Sermorelin (Geref) is currently used clinically to assess growth hormone secretion, but peptides are even more interesting because of their following abilities:
– Increase bone density
– Improves nutrition in chronic illness
– Reduce scarring after a heart attack
– Improves renal function
– Reduce seizure activity
– Fights the effects of dementia
Sermorelin and Heart Disease
A heart attack is an acute life-threatening event. Still, it can also lead to long-term disorders such as heart failure, cardiac conduction disorders (arrhythmias), impaired motor skills, and pain. Many of these problems result from cardiac remodeling following damage to 4,444 muscle cells (cardiomyocytes).
Cardiac remodeling often results in scarring in the damaged area after a heart attack and in the surrounding undamaged area. This remodeling causes many long-term problems, and studies have shown that preventing them can significantly improve results immediately after a heart attack and years later.
In 2016, a study showed that administration of sermorelin was effective in reducing post-cardiac remodeling. Studies show that sermorelin:
– Reduces cardiomyocyte cell death
– Increases the production of extracellular matrix components needed for proper healing
– Increases the growth of blood vessels into damaged tissue and is harmful
– Reduce the production of substances that cause inflammation
Clinically, the effects of sermorelin have been shown to improve diastolic function, reduce scar size and increase capillary growth.
Current studies are investigating the benefits of sermorelin in other forms of heart disease such as heart failure and valvular heart disease. GHRH treatment reduces the amount of scarring.
Sermorelin and Epilepsy
Gamma-aminobutyric acid (GABA) is a central nervous system signaling molecule known to reduce the electrical activity of the spinal cord and reduce the overall electrical excitability of the central nervous system. Many antiepileptic medications work by increasing GABA levels in the central nervous system or by binding to GABA receptors and mimicking GABA effects.
In a recent study of mice with epilepsy, scientists administered GHRH analogs, such as Sermorelin to test the effect of these peptides on seizure activity. The GHRH analog was found to be effective in suppressing seizures by activating GABA receptors.
Regulates Sleep Cycles
There is ample evidence that the sleep cycle is regulated by orexin, a powerful neurochemical produced by specific neurons in the brain. It is also common knowledge that growth and healing, closely related to the release of growth hormone, occur primarily during sleep.
Studies at Rainbow suggest that this is not a coincidence, as the intact GHRH axis is necessary for orexin to secrete and function properly. In addition, Study shows that extrinsic administration of sermorelin and other GHRH agonists may increase orexin secretion.
Sermorelin Increases Muscle Mass and Promotes Long Bone Growth
Sermorelin is a growth hormone-releasing hormone derivative that has all the same effects that GH produces, such as increasing muscle mass, promoting long bone growth, and reducing adipose tissue. The effect is the same, but there are no side effects.
Sermorelin is the preferred method for increasing human GH levels over extrinsic growth hormone administration. The main reason for this priority is that sermorelin is affected by physiological feedback mechanisms that contribute to the general problems associated with the administration of GH avoidance.
These problems include unintended side effects such as overdose, inadequate doses, edema, joint pain, and dysregulation of normal physiology. The second reason to like sermorelin is that studies show that it does not develop tachyphylaxis.
Tachyphylaxis is when the body gets used to the medication and requires higher doses to achieve the desired effect. In some cases, tachyphylaxis is so severe that a substance leave (complete discontinuation of use) is required to regain the medication’s effect.
Body Response and Side Effects
Long-term use of sermorelin in certain clinical situations, and animal studies of peptides, show that the body responds uniquely to the peptide. Instead of downregulating the production of GHRH receptors by administering Sermorelin, the body instead increases its production.
This ensures that the effects of sermorelin do not change, that tachyphylaxis does not develop significantly, and that there is generally no need to increase the dose.
Sermorelin exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. The dose per kg of mice is not tailored for humans.
NOTE: The information found in this article is intended for educational or informational purposes only. Some or all of the content in these articles are not substantiated by a medical professional and may be based on the opinions of the writer, who may not be a medical or accredited professional. Not intended for personal use. Please review our Terms and Conditions.